In a recent study, Sheng et al. have explored in a large number of 10,053 Chinese breast cancer patients the incidence of germline TP53 mutations: in the overall population 0.5% of patients carried a pathogenic TP53 germline mutation and 3.8% in very early onset (<30 years) breast cancer [335]. This evidence concerns the gene TP53 and breast carcinoma.